Atrial fibrillation: Advances and perspectives

Dialogues in Cardiovascular Medicine

Volumn 8, Issue 4, 2003, Pages 183-202

  Camm, A John ^a   Savelieva, Irina ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antiarrhythmic drug; Anticoagulation; Atrial fibrillation; Catheter ablation; Defibrillator; Elderly; Epidemiology; Pacemaker; Prevention; Sinus rhythm

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; CLOPIDOGREL; IRBESARTAN; WARFARIN; XIMELAGATRAN;

AGE DISTRIBUTION; ANTICOAGULATION; AUTONOMIC DYSFUNCTION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DISEASE EXACERBATION; DRUG EFFICACY; DRUG POTENTIATION; GENETIC DISORDER; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACEMAKER; HEART CATHETERIZATION; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART FUNCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PROARRHYTHMIA; HEART SURGERY; HEART VENTRICLE TACHYCARDIA; HUMAN; LIVER TOXICITY; LONG QT SYNDROME; MEDICAL CARE; PALLIATIVE THERAPY; PATHOGENESIS; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SINUS NODE DISEASE; SINUS RHYTHM; SYMPTOMATOLOGY; THROMBOEMBOLISM;

EID: 1842558673     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Hering HE. Das Electrokardiogramm des Pulsus irregularis perpetuus [Electrocardiogram of permanent irregular pulse]. Deutch Arch Klin Med. 1908;94:205-208.
2. Rothberger CJ, Winterberg H. Vorhofflimmern and Arrhythmia perpetua [Atrial fibrillation and permanent arrhythmia]. Wiener Klin Wochenschr. 1909;22:839-844.
3. Lewis T. Auricular fibrillation: A common clinical condition. BMJ. 1909;2:1528.
4. Lewis T. Evidences of auricular fibrillation, treated historically. BMJ. 1912;13:59.
5. Lewis T, Schleiter HG. The relation of regular tachycardias of auricular origin to auricular fibrillation. Heart. 1912;3:173-193.
6. Rothberger CJ, Winterberg H. Über Vorhofflimmern und Vorhofflattern [About atrial fibrillation and atrial flutter]. Pflügers Arch Gesam Physiol Mensch Tier. 1915;160:42-90.
7. Lewis T, Feil HS, Stroud WD. Observations upon flutter and fibrillation. II. The nature of auricular flutter. Heart. 1920;7:191-233.
8. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustained arrhythmia independent of focal discharge. Am Heart J. 1959;58:59-70.
9. Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The leading circle concept: A new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res. 1977;41:9-18.
10. Evans W, Swann P. Lone auricular fibrillation. Am Heart J. 1953;189-194.
11. Lown B. Electrical reversion of cardiac arrhythmias. Thomas Lewis Lecture. Br Heart J. 1967;29:469-489.
12. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA. 1994;271:840-844.
13. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: The AnTi-coagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
14. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455-2461.
15. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: Prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol. 2000;4:369-382.
16. Acar J, Michel PL, Cormier B, Vahanian A, Iung B. Features of patients with severe mitral stenosis with respect to atrial rhythm: atrial fibrillation in predominant and tight mitral stenosis. Acta Cardiol. 1992;47:115-124.
17. Krahn AD, Klein GJ, Kerr CR, et al, for the Canadian Registry of Atrial Fibrillation Investigators. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? Arch Intern Med. 1996;156:2221-2224.
18. Koskinen P, Kupari M, Leinonen H, Luomanmaki K. Alcohol and new onset atrial fibrillation: A case-control study of a current series. Br Heart J. 1987;57:468-473.
19. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM, for the GUSTO-I Trial Investigators. Atrial fibrillation in the setting of acute myocardial infarction: The GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol. 1997;30:406-413.
20. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999;281:610-655.
21. Kirsh JA, Walsh EP, Triedman JK. Prevalence of and risk factors for atrial fibrillation and intra-atrial reentrant tachycardia among patients with congenital heart disease. Am J Cardiol. 2002;90:338-340.
22. Campbell RW, Smith RA, Gallagher JJ, Pritchett EL, Wallace AG. Atrial fibrillation in the preexcitation syndrome. Am J Cardiol. 1977;40:514-520.
23. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180-1184.
24. Tsang TS, Gersh BJ, Appleton CP, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40:1636-1644.
25. Ciaccheri M, Cecchi F, Arcangeli C, Dolara A, Zuppiroli A, Pieroni C. Occult thyrotoxicosis in patients with chronic and paroxysmal isolated atrial fibrillation. Clin Cardiol. 1984;7:413-416.
26. Maixent JM, Paganelli F, Scaglione J, Levy S. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9:612-617.
27. Schauerte P, Scherlag BJ, Patterson E, et al. Focal atrial fibrillation: Experimental evidence for a pathophysiologic role of the autonomic nervous system. J Cardiovasc Electrophysiol. 2001;12:592-599.
28. De Sisti A, Leclercq JF, Fiorello P, et al. Sick sinus syndrome with and without atrial fibrillation: Atrial refractoriness and conduction characteristics. Cardiologia. 1999;44:361-367.
29. Brugada R, Brugada J, Roberts R. Genetics of cardiovascular disease with emphasis on atrial fibrillation. J Interv Card Electrophysiol. 1999;3:7-13.
30. Levy S, Maarek M, Coumel P, et al, on behalf of the College of French Cardiologists. Characterization of different subsets of atrial fibrillation in general practice in France: The ALFA Study. Circulation. 1999;99:3028-3035.
31. Cleland JGF, Swedberg K, Follath F, et al, for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J. 2003;24:442-463.
32. Culler MR, Boone JA, Gazes PC. Fibrillatory wave size as a clue to etiologic diagnosis. Am Heart J. 1963;66:434.
33. Konings KTS, Kirchhof CJHJ, Smeets JRLM, Wellens HJ, Penn OC, Allessie MA. High density mapping of electrically induced atrial fibrillation in humans. Circulation. 1994;89:1665-1680.
34. Saksena S, Giorgberidze I, Mehra R, et al. Electrophysiology and endocardial mapping of induced atrial fibrillation in patients with spontaneous atrial fibrillation. Am J Cardiol. 1999;83:187-193.
35. Horvath G, Godberger JJ, Kadish AH. Simultaneous occurrence of atrial fibrillation and atrial flutter. J Cardiovasc Electrophysiol. 2000;22:849-858.
36. Pandozi C, Biankoni L, Villani M, et al. Local capture by atrial pacing in spontaneous chronic atrial fibrillation. Circulation. 1997;95:2416-2422.
37. Capucci A, Ravelli F, Nollo G, Montenero AS, Biffi M, Villani GQ. Capture window in human atrial fibrillation: Evidence of excitable gap. J Cardiovasc Electrophysiol. 1999;10:319-327.
38. Haisaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659-666.
39. Allessie MA, Boyden PA, Camm AJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation. 2001;103:769-777.
40. Dauod EG, Bogun F, Goyal R, et al. Effects of atrial fibrillation on atrial refractoriness in humans. Circulation. 1996;94:1600-1606.
41. Pandozi C, Baianconi L, Villani M, et al. Electrophysiological characteristics of the human atria after cardioversion of persistent atrial fibrillation. Circulation. 1998;98:2860-2865.
42. Ausma J, Litijens N, Lenders MH, et al. Time course of atrial fibrillation-induced cellular structural remodeling in atrial of the goat. J Mol Cell Cardiol. 2001;33:2083-2094.
43. Ausma J, Van Der Velden HMW, Lenders MH, et al. Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. Circulation. 2003;107:2051-2058.
44. Hobbs WJ, Van Gelder IC, Fitzpatrick AP, Crijns HJ, Garratt CJ. The role of atrial electrical remodeling in the progression of focal atrial activity to persistent atrial fibrillation. J Cardiovasc Electrophysiol. 1999;10:866-870.
45. Elvan A, Zipes DP. Pacing induced chronic atrial fibrillation impairs sinus node function in dogs. Circulation. 1997.
46. Lüderitz B, Jung W. Quality of life in atrial fibrillation. J Interv Card Electrophysiol. 2000;4(suppl 1):201-209.
47. Savelieva I, Paquette M, Dorian P, Lüderitz B, Camm AJ. Quality of life in patients with silent atrial fibrillation. Heart. 2001;85:216-217.
48. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel W, Levy D. Impact of atrial fibrillation on risk of death: The Framingham Study. Circulation. 1999;98:946-952.
49. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as independent risk factor for stroke: The Framingham Study. Stroke. 1991;22:983-988.
50. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119:194S-206S.
51. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628-1637.
52. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation. 1991;84:40-48.
53. Jouven X, Desnos M, Guerot C, Ducimetiere P. Idiopathic atrial fibrillation as a risk for mortality: The Paris Prospective Study I. Eur Heart J. 1999;20:896-899.
54. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158:229-234.
55. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation: The Copenhagen Stroke Study. Stroke. 1996;27:1765-1769.
56. Mathew J, Hunsberger S, Fleg J. Mc Sherry F, Williford W, Yusuf S, for the Digitalis Investigation Group. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest. 2000;118:914-922.
57. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Study. Circulation. 2003;107:2920-2925.
58. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinmann MM. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709-715.
59. Fuster V, Rydén LE, Asinger RV, et al. Task Force Report: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J. 2001;22:1852-1923.
60. Huang DT, Monahan KM, Zimetbaum P, Papageorgiou P, Epstein LM, Josephson ME. Hybrid pharmacologic and ablative therapy: A novel and effective approach for the management of atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9:462-469.
61. Camm AJ, Savelieva I. Rationale and patient selection for "DYbrid" drug and device therapy in atrial and ventricular arrhythmias. J Interv Card Electrophysiol. 2003;9:207-214.
62. Saskena S, Domanski MJ, Benjamin EJ, et al. Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation. North American Society of Pacing and Electrophysiology. J Interv Card Electrophysiol. 2001;5:345-364.
63. Koide Y, Yotsukura M, Sakata K, Yoshino H, Ishikawa K. Investigation of the predictors of transition to persistent atrial fibrillation in patients with paroxysmal atrial fibrillation. Clin Cardiol. 2002;25:69-75.
64. Al Khatib SM, Wilkinson WE, Sanders LL, McCarthy EA, Pritchett EL. Observations on the transition from intermittent to permanent atrial fbrillation. Am Heart J. 2000;140:142-145.
65. Klein AL, Grimm RA, Murray RD, et al, for the Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411-1420.
66. Crijns HJ, Van Gelder IC, Lie KI. Benefits and risks of antiarrhythmic drug therapy after DC electrical cardioversion of atrial fibrillation or flutter. Eur Heart J. 1994;15(suppl A):17-21.
67. Reiffel JA. Drug choices in the treatment of atrial fibrillation. Am J Cardiol. 2000;85:12D-19D.
68. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999;100:2025-2034.
69. Hohnloser SH, Kuck KH, Lilienthal J, for the PIAF Investigators. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet. 2000;356:1789-1794.
70. Carlsson J, Miketic S, Windeler J, et al, for the STAF Investigators. Randomized trial of rate control versus rhythm control in persistent atrial fibrillation: The Strategies of Treatment in Atrial Fibrillation (STAF) Study. J Am Coll Cardiol. 2003;41:1690-1696.
71. Van Gelder IC, Hagens VE, Bosker HA, et al, for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840.
72. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
73. Opolski G, Torbicki A, Kosior D, et al. Rate control versus rhythm control in patients with nonvalvular chronic atrial fibrillation: the results of HOT CAFE Polish Study. Eur Heart J. 2002;4:486 (Abstract).
74. Vora AM, Goyal VS, Naik AM, et al. Maintenance of sinus rhythm by amiodarone is superior to ventricular rate control in rheumatic atrial fibrillation: A blinded placebo controlled study.
75. Page RL, Tilsh TW, Connolly SJ, et al, for the Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or "AIlent" atriFl fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation. 2003;107:1141-1145.
76. Blackshear JL, Pearce LA, Hart RG, et al. Aortic plaque in atrial fibrillation: Prevalence, predictors, and thromboembolic implications. Stroke. 1999;30:834-840.
77. Epstein AE, Corley SD, and the AFFIRM Investigators. Relationships between sinus rhythm, treatment and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2003;108:IV472. Abstract.
78. Kay GN. Catheter ablation of atrial fibrillation: Challenges and promise. Am J Cardiol. 2000;86:K25-K27.
79. Savelieva I, Camm AJ. The results of pacing trials for the prevention and termination of atrial tachyarrhythmias: Is there any evidence of therapeutic breakthrough? J Interv Card Electrophysiol. 2003;8:103-115.
80. Savelieva I, Camm AJ. Antitachycardia pacing of for termination of atrial tachyarrhythmias. In: Israel CW, Barold SS, eds. Advances in the Treatment of Atrial Tachyarrhythmias: Pacing, Cardioversion, and Defibrillation. Armonk, NY: Futura Publishing Co; 2002:339-368.
81. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillatiTA: Evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol. 1994;23:307-316.
82. Al-Saady NM, Sopher M. Prothrombotic markers in atrial fibrillation: What is new? Eur Heart J. 2001;22:1639-1641.
83. Seidl K, Rameken M, Drögemüller A, et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: Value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshaften Observational Cardioversion Study. J Am Coll Cardiol. 2002;39:1436-1442.
84. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med. 1999;131:492-501.
85. Hart RG, Pearce LA, McBride R, et al, for the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III clinical trials. Stroke. 1999;30:1223-1229.
86. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000;35:183-187.
87. Petersen P, Boysen G, Godtfredsen L, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. Lancet. 1989;1:175-179.
88. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327:1406-1412.
89. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-355.
90. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
91. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation. 1991;84:527-539.
92. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med. 1998;128:639-647.
93. Sievert H, Lesh M, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high risk patients with atrial fibrillation: Early clinical experience. Circulation. 2002;105:1887-1889.
94. Nakai T, Lesh MD, Gerstenfeld EP, Virmani R, Jones R, Lee RJ. Percutaneous left atrial appendage occlusion (PLAATO) for preventing cardioembolism: First experience in canine model. Circulation. 2002;105:2217-2222.
95. Scheimann MM, Morady F, Hess DS, Gonzalez R. Catheter-induced ablation of the atrioventricular function to control refractory supraventricular arrhythmias. JAMA. 1982;248:851-855.
96. Kay GN, Ellenbogen KA, Giudici M, et al. The Ablate and Pace Trial: A prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. J Interv Card Electrophysiol. 1998;2:121-135.
97. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A meta-analysis. Circulation. 2000;101:1138-1144.
98. Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia. Circulation. 2000;102:2619-2628.
99. Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation. 2002;105:1077-1081.
100. Deneke T, Khargi K, Grewe PH, et al. Efficacy of an additional MAZE procedure using cooled-tip radio-frequency ablation in patients with chronic atrial fibrillation and mitral valve disease: A randomized, prospective trial. Eur Heart J. 2002;23:558-566.
101. Cox JL, Boineau JP, Schuessler RB, et al. Successful surgical treatment of atrial fibrillation. JAMA. 1991;266:1976-1980.
102. Scheinman MM, Morady F. Nonpharmacological approaches to atrial fibrillation. Circulation. 2001;103:2120-2125.
103. Bailin SJ, Adler S, Giudici M. Prevention of chronic atrial fibrillation by pacing in the region of Bachmann's bundle: Results of a multicenter randomized trial. J Cardiovasc Electrophysiol. 2001;12:912-917.
104. Saksena S, Prakash A, Ziegler P, et al, for the DAPPAF Investigators. The Dual-site Atrial Pacing for Prevention of Atrial Fibrillation (DAPPAF) trial: Improved suppression of atrial fibrillation with dual-site atrial pacing and antiarrhythmic drug therapy. J Am Coll Cardiol. 2002;40:1140-1150.
105. D'Allonnes GR, Pavin D, Leclercq C, et al. Long-term effects of biatrial synchronous pacing to prevent drug-refractory atrial tachyarrhythmia: A nine-year experience. J Cardiovasc Electrophysiol. 2000;11:1081-1091.
106. Carlson MD, Gold MR, Ip J, Messenger J, Beau S, Cameron D, for the ADOPT Investigators. Dynamic atrial overdrive pacing decreases symptomatic atrial arrhythmia burden in patients with sinus node dysfunction. Circulation. 2001;23:II383. Abstract.
107. Israel CW, Ehrlich JR, Grönefeld G, et al. Prevalence, characteristics and clinical implications of regular atrial tachyarrhythmias in patients with atrial fibrillation: Insights from a study using a new implantable devices. J Am Coll Cardiol. 2001;38:355-363.
108. Giorgberidze I, Saksena S, Mongeon L, et al. Effects of high-frequency atrial pacing in atypical atrial flutter and atrial fibrillation. J Interv Card Electrophysiol. 1997;1:111-123.
109. Friedman PA, Dijkman B, Warman EN, et al, for the Worldwide Jewel AF Investigators. Atrial therapies reduce atrial arrhythmia burden in defibrillator patients. Circulation. 2001;104:1023-1028.
110. Mabo P, Funck R, De Roy L, et al. Impact of ventricular pacing on atrial fibrillation prevention. Pacing Clin Electrophysiol. 2002;24:621. Abstract.
111. Reithmann C, Hoffmann E, Spitzlberger G, et al. Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. Eur Heart J. 2000;21:565-572.
112. Krol R, Saksena S, Prakash A. New devices and hybrid therapies for treatment of atrial fibrillation. J Interv Card Electrophysiol. 2000;4:163-169.
113. Pederson OD, Bagger H, Køber L, et al, for the TRACE Study Group. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376-380.
114. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the studies of left ventricular dysfunction. Circulation. 2003;107:2926-2931.
115. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;49:762-770.
116. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. Circulation. 2003;41:2197-2204.
117. Hernandez-Madrid A, Bueno MG, Rebollo JG, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation. 2002;39:106:331-336.